Home / News / CMS advised Syncona Ltd on investment in Anaveon...

CMS advised Syncona Ltd on investment in Anaveon AG

CMS advised Syncona Ltd on investment in Anaveon AG

Syncona Ltd leads a CHF 35 million financing in Anaveon AG, a new immuno-oncology company. Anaveon AG is developing a selective IL-2 Receptor Agonist, a type of protein that could therapeutically enhance a patient’s immune system to respond to tumours. In the body, human IL-2 stimulates a type of immune cell, called a T-cell, to multiply and become activated. Under certain situations, T-cells are able to attack tumours and, consistent with this, human IL-2 is already approved as a medicine for the treatment of metastatic melanoma and renal cancer.

Syncona is a leading healthcare company focused on founding, building and funding global leaders in life science. Anaveon is Syncona’s tenth life science company following the investment in OMass Therapeutics in August 2018.

A team of CMS Switzerland led by Stefan Brunnschweiler has advised Syncona on all legal aspects of the investment.


CMS Switzerland
Stefan Brunnschweiler, Partner, Corporate/M&A
Dr Felix Kesselring, Counsel, Life Sciences & Healthcare
Dr Simone Brauchbar Birkhäuser, Counsel, Intellectual Property
Florian Jung, Associate, Corporate/M&A


For more information, please visit:

Syncona Ltd
Anaveon AG

Related people

Portrait of Stefan Brunnschweiler
Stefan Brunnschweiler, LL.M.
Managing Partner
Portrait of Simone Brauchbar Birkhäuser, LL.M.
Dr Simone Brauchbar Birkhäuser, LL.M.
Portrait of Florian Jung
Florian Jung, LL.M.
Senior Associate
Dr Felix Kesselring, LL.M. (LSE)
Show more Show less